Lipitor

Phase 3Small molecule

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Lipitor is one of 134 small molecule programs targeting Toxicity. It is currently in Phase 3.

Indications

Total Trials

Active Trials

133

Competitors

Pipeline

Status by Indication[3][1]

Indication

ToxicityActive, not recruiting

Kidney TransplantActive, not recruiting

Polycystic Ovary SyndromeActive, not recruiting

HypercholesterolemiaActive, not recruiting

ToxicityPhase 2

Active, not recruiting

Kidney TransplantPreclinical

Active, not recruiting

Polycystic Ovary SyndromePhase 2

Active, not recruiting

HypercholesterolemiaPhase 3

Active, not recruiting

Competition

Competitive Landscape

476 competitors in Kidney Transplant

#DrugCompanyPhaseTrials

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 2

Nulojix

Bristol-Myers Squibb

Preclinical

16 3

Simulect

Novartis

Preclinical

15 4

Medrol

Pfizer

Preclinical

12 5

Zinbryta

Roche

Preclinical

6 6

Cysteine Hydrochloride

Novartis

Preclinical

1 7

Sensipar

Amgen

Preclinical

1 8

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

1 9

Radicava

Shionogi

Preclinical

1 10

Jardiance

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Toxicity

NCT05559164

Clinical

Trials by Indication[1]

Atorvastatin2 trials

Atorvastatin Versus Ezetimibe and Fenofibrate as a Lipid-lowering Strategy

Completed·QQueen's University··NCT00299884·45 enrolled

Bioavailability Study for New Atorvastatin Formulation

Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 4·NCT00844376·12 enrolled

Dialysis Patients1 trial

Effect of Statins on IgG, IgA and IgM Level in Chronic Hemodialysis Patients

Completed·HHormozgan University of Medical Sciences·N/A·NCT01305317·74 enrolled

Polycystic Ovary Syndrome1 trial

A Trial of Lipitor (Atorvastatin) for the Treatment of Polycystic Ovary Syndrome (PCOS) in Women With Elevated Low-density Lipoprotein (LDL) Cholesterol

Completed·MMilton S. Hershey Medical Center·Phase 2·NCT00529542·20 enrolled

Kidney Transplant1 trial

Pediatric Kidney Transplant Without Calcineurin Inhibitors

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00023231·35 enrolled

Magnetic Resonance Imaging1 trial

Effects of Statins on Lower Extremity Arterial Function Assessed by Magnetic Resonance Imaging

Terminated·JJohns Hopkins University·N/A·NCT00770679·16 enrolled

5 more indications

Toxicity1 trial

Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted

Recruiting·RRutgers, The State University of New Jersey·Phase 2·NCT05559164·60 enrolled

Mitochondria1 trial

Impact of Statin Therapy on Muscle Mitochondrial Function and Aerobic Capacity

Completed·UUniversity of Kansas Medical Center·Phase 4·NCT03351998·68 enrolled

Exercise1 trial

Impact of Statin Therapy on Adaptations to Aerobic Exercise

Completed·UUniversity of Kansas Medical Center·Phase 4·NCT03360916·52 enrolled

Hypercholesterolemia1 trial

Efficacy and Safety Study of Pitavastatin for Hypercholesterolemia

Completed·OOrient Pharma Co., Ltd.·Phase 3·NCT01710007·202 enrolled

Pediatric1 trial

Bioequivalence Study On Pediatric Appropriate Formulation

Completed·PPfizer's Upjohn has merged with Mylan to form Viatris Inc.·Phase 1·NCT00777517·76 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for Lipitor. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lipitor compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lipitor. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer's Upjohn has merged with Mylan to form Viatris Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Lipitor

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Atorvastatin2 trials

Dialysis Patients1 trial

Polycystic Ovary Syndrome1 trial

Kidney Transplant1 trial

Magnetic Resonance Imaging1 trial

Toxicity1 trial

Mitochondria1 trial

Exercise1 trial

Hypercholesterolemia1 trial

Pediatric1 trial

References

Drug Info

Quick Facts

Related News